|
1
|
Bray F, Ferlay J, Soerjomataran I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Cunningham D, Starling N, Rao S, Iveson T,
Nicolson M, Coxon F, Middleton G, Daniel F, Oates J and Norman AR:
Capecitabine and oxaliplatin for advanced esophagogastric cancer. N
Engl J Med. 358:36–46. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Wagner AD, Grothe W, Haerting J, Kleber G,
Grothey A and Fleig WE: Chemotherapy in advanced gastric cancer: A
systematic review and meta-analysis based on aggregate data. J Clin
Oncol. 24:2903–2909. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bang YJ, Van Cutsem E, Feyereislova A,
Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T,
et al: Trastuzumab in combination with chemotherapy versus
chemotherapy alone for treatment of HER2-positive advanced gastric
or gastro-oesophageal junction cancer (ToGA): A phase 3,
open-label, randomised controlled trial. Lancet. 376:687–697. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Fuchs CS, Tomasek J, Yong CJ, Dumitru F,
Passalacqua R, Goswami C, Safran H, Dos Santos LV, Aprile G, Ferry
DR, et al: REGARD Trial Investigators. Ramucirumab monotherapy for
previously treated advanced gastric or gastro-oesophageal junction
adenocarcinoma (REGARD): An international, randomised, multicentre,
placebo-controlled, phase 3 trial. Lancet. 383:31–39. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wilke H, Muro K, Van Cutsem E, Oh SC,
Bodoky G, Shimada Y, Hironaka S, Sugimoto N, Lipatov O, Kim TY, et
al: Ramucirumab plus paclitaxel versus placebo plus paclitaxel in
patients with previously treated advanced gastric or
gastro-oesophageal junction adenocarcinoma (RAINBOW): A
double-blind, randomised phase 3 trial. Lancet Oncol. 15:1224–1235.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Li J, Qin S, Xu J, Xiong J, Wu C, Bai Y,
Liu W, Tong J, Liu Y, Xu R, et al: Randomized, double-blind,
placebo-controlled phase III trial of apatinib in patients with
chemotherapy-refractory advanced or metastatic adenocarcinoma of
the stomach or gastroesophageal junction. J Clin Oncol.
34:1448–1454. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Pavlakis N, Sjoquist KM, Martin AJ,
Tsobanis E, Yip S, Kang YK, Bang YJ, Alcindor T, OCallaghan CJ,
Burnell MJ, et al: Regorafenib for the treatment of advanced
gastric cancer (INTEGRATE): A multinational placebo-controlled
phase II Trial. J Clin Oncol. 34:2728–2735. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kang YK, Rha SY, Tassone P, Barriuso J, Yu
R, Szado T, Garg A and Bang YJ: A phase IIa dose-finding and safety
study of first-line pertuzumab in combination with trastuzumab,
capecitabine and cisplatin in patients with HER2-positive advanced
gastric cancer. Br J Cancer. 111:660–666. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Fujitani K, Yang HK, Mizusawa J, Kim YW,
Terashima M, Han SU, Iwasaki Y, Hyung WJ, Takagane A, Park DJ, et
al: Gastrectomy plus chemotherapy versus chemotherapy alone for
advanced gastric cancer with a single non-curable factor (REGATTA):
A phase 3, randomised controlled trial. Lancet Oncol. 17:309–318.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Samarasam I, Chandran BS, Sitaram V,
Perakath B, Nair A and Mathew G: Palliative gastrectomy in advanced
gastric cancer: Is it worthwhile? ANZ J Surg. 76:60–63. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hartgrink HH, Putter H, Klein Kranenbarg
E, Bonenkamp JJ and van de Velde CJ; Dutch Gastric Cancer Group, :
Value of palliative resection in gastric cancer. Br J Surg.
89:1438–1443. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Medina-Franco H, Contreras-Saldívar A,
Ramos-De La Medina A, Palacios-Sanchez P, Cortés-González R and
Ugarte JA: Surgery for stage IV gastric cancer. Am J Surg.
187:543–546. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Fornaro L, Fanotto V, Musettini G, Uccello
M, Rimassa L, Vivaldi C, Fontanella C, Leone F, Giampieri R, Rosati
G, et al: Selecting patients for gastrectomy in metastatic
esophago-gastric cancer: Clinics and pathology are not enough.
Future Oncol. 13:2265–2275. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Sun J, Song Y, Wang Z, Chen X, Gao P, Xu
Y, Zhou B and Xu H: Clinical significance of palliative gastrectomy
on the survival of patients with incurable advanced gastric cancer:
A systematic review and meta-analysis. BMC Cancer. 13:5772013.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Mohri Y, Tanaka K, Ohi M, Saigusa S,
Yasuda H, Toiyama Y, Araki T, Inoue Y and Kusunoki M:
Identification of prognostic factors and surgical indications for
metastatic gastric cancer. BMC Cancer. 14:4092014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Gadde R, Tamariz L, Hanna M, Avisar E,
Livingstone A, Franceschi D and Yakoub D: Metastatic gastric cancer
(MGC) patients: Can we improve survival by metastasectomy? A
systematic review and meta-analysis. J Surg Oncol. 112:38–45. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Rudloff U, Langan RC, Mullinax JE, Beane
JD, Steinberg SM, Beresnev T, Webb C, Walker M, Toomey MA, Schrump
D, et al: Impact of maximal cytoreductive surgery plus regional
heated intraperitoneal chemotherapy (HIPEC) on outcome of patients
with peritoneal carcinomatosis of gastric origin: Results of the
GYMSSA trial. J Surg Oncol. 110:275–284. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Scartozzi M, Loretelli C, Galizia E,
Mandolesi A, Pistelli M, Bittoni A, Giampieri R, Faloppi L,
Bianconi M, Del Prete M, et al: Role of vascular endothelial growth
factor (VEGF) and VEGF-R genotyping in guiding the metastatic
process in pT4a resected gastric cancer patients. PLoS One.
7:e381922012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Scartozzi M, Giampieri R, Loretelli C,
Bittoni A, Mandolesi A, Faloppi L, Bianconi M, Del Prete M,
Andrikou K, Bearzi I and Cascinu S: Tumor angiogenesis genotyping
and efficacy of first-line chemotherapy in metastatic gastric
cancer patients. Pharmacogenomics. 14:1991–1998. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Iijima Y, Akiyama H, Atari M, Fukuhara M,
Nakajima Y, Kinosita H and Hidetaka U: Pulmonary resection for
metastatic gastric cancer. Ann Thorac Cardiovasc Surg. 22:230–236.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yoshida Y, Imakiire T, Yoneda S, Obuchi T,
Inada K and Iwasaki A: Ten cases of resected solitary pulmonary
metastases arising from gastric cancer. Asian Cardiovasc Thorac
Ann. 22:578–582. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Riihimäki M, Hemminki A, Sundquist K,
Sundquist J and Hemminki K: Metastatic spread in patients with
gastric cancer. Oncotarget. 7:52307–52316. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Van Raemdonck D: Pulmonary metastasectomy:
Common practice but is it also best practice? Futur Oncol.
11:11–14. 2015. View Article : Google Scholar
|
|
25
|
Treasure T, Fallowfield L and Lees B:
Pulmonary metastasectomy in colorectal cancer: The PulMiCC trial. J
Thorac Oncol. 5 (6 Suppl 2):S203–S206. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Gonzalez M and Gervaz P: Risk factors for
survival after lung metastasectomy in colorectal cancer patients:
Systematic review and meta-analysis. Future Oncol. 11 (Suppl
2):S31–S33. 2015. View Article : Google Scholar
|
|
27
|
Cancer Genome Atlas Research Network, .
Comprehensive molecular characterization of gastric adenocarcinoma.
Nature. 513:202–209. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Lauren P: The two histological main types
of gastric carcinoma: Diffuse and so-called intestinal-type
carcinoma. An attempt at a histo-clinical classification. Acta
Pathol Microbiol Scand. 64:31–49. 1965. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Chen YC, Fang WL, Wang RF, Liu CA, Yang
MH, Lo SS, Wu CW, Li AF, Shyr YM and Huang KH: Clinicopathological
variation of lauren classification in gastric cancer. Pathol Oncol
Res. 22:197–202. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Schwartz LH, Litière S, de Vries E, Ford
R, Gwyther S, Mandrekar S, Shankar L, Bogaerts J, Chen A, Dancey J,
et al: RECIST 1.1-update and clarification: From the RECIST
committee. Eur J Cancer. 62:132–137. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Bittoni A, Scartozzi M, Giampieri R,
Faloppi L, Bianconi M, Mandolesi A, Del Prete M, Pistelli M,
Cecchini L, Bearzi I and Cascinu S: Clinical evidence for three
distinct gastric cancer subtypes: Time for a new approach. PLoS
One. 8:e785442013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Petrelli F, Berenato R, Turati L, Mennitto
A, Steccanella F, Caporale M, Dellera P, de Braud F, Pezzica E, Di
Bartolomeao M, et al: Prognostic value of diffuse versus intestinal
histotype in patients with gastric cancer: A systematic review and
meta-analysis. J Gastrointest Oncol. 8:148–163. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Fanotto V, Cordio S, Pasquini G,
Fontanella C, Rimassa L, Leone F, Rosati G, Santini D, Giampieri R,
Di Donato S, et al: Prognostic factors in 868 advanced gastric
cancer patients treated with second-line chemotherapy in the real
world. Gastric Cancer. 20:825–833. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Brandi G, Derenzini E, Falcone A, Masi G,
Loupakis F, Pietrabissa A, Pinna AD, Ercolani G, Pantaleo MA, Di
Girolamo S, et al: Adjuvant systemic chemotherapy after putative
curative resection of colorectal liver and lung metastases. Clin
Colorectal Cancer. 12:188–194. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Aurello P, Petrucciani N, Giulitti D,
Campanella L, DAngelo F and Ramacciato G: Pulmonary metastases from
gastric cancer: Is there any indication for lung metastasectomy? A
systematic review. Med Oncol. 33:92016. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Shiono S, Sato T, Horio H, Chida M,
Matsuguma H, Ozeki Y, Nakajima J and Okumura S; Metastatic Lung
Tumor Study Group of Japan, : Outcomes and prognostic factors of
survival after pulmonary resection for metastatic gastric cancer.
Eur J Cardiothorac Surg. 43:e13–e16. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Bittoni A, Del Prete M, Scartozzi M,
Pistelli M, Giampieri R, Faloppi L, Bianconi M and Cascinu S: Three
vs. two drugs first-line chemotherapy regimen in advanced gastric
cancer patients: A retrospective analysis. Springerplus. 4:7432015.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Zieliński M, Ochman M, Głowacki J and
Kozielski J: Pulmonary lesions in the course of gastric cancer-two
cases of Bards syndrome. Pneumonol Alergol Pol. 84:33–37. 2016.
View Article : Google Scholar : PubMed/NCBI
|
